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Abstract 
Erythropoietin is the major regulating blood flow hormone which can be effect on hematopoiesis of 
premature infants. The aim of this study was to examine the effectiveness of intravenous recombinant 
erythropoietin regimen associated with oral iron in hematopoiesis of premature infants. This is a randomized 
clinical trial that has been done on 80 (40 persons in each group) very low and premature infants. First group 
received intravenous recombinant erythropoietin (with 400 units per kg weight in day (3 days in week)) 
associated with iron drip and second group as control group iron administrated only. All information were 
entered in a checklist and analyzed by statistical methods in SPSS.16. In case group 62.5% and in control group 
60% were boy. The average weight of cases was 1273.8  ±198.4 gr and controls were 1223.8  ±217.5 gr. The 
injection of erythropoietin could be significantly prevent the decreasing of hemoglobin and ferritin and leads to 
increase in reticulocytes levels in cases but not have significantly on Iron level. Results showed that injection of 
erythropoietin in premature infants deal to increasing reticulocyte, Hb and ferritin levels in case group and the 
results was similar with studies in other places.  
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Introduction 
Prematurity-induced anemia is a type of 
normocytic anemia with low reticulocyte number. It 
usually appears two weeks after birth and reaches 
highest intensity during the second month. It is 
usually identified through a reduction in 
reticulocyte and an inadequate response to 
erythropoietin in many premature neonates who 
frequently need blood transfusion. 
Erythropoietin is an important factor in 
hematopoiesis from fetal period up to neonatal 
period and maturity and leads to erythrocyte 
division and its greater longevity through inhibiting 
apoptosis of erythroid precursors.  
Previously, erythropoietin was assumed to be 
merely a cytokine affecting hematopoiesis, but 
recently its receptors have been proven to be very 
diverse and of utility in the evolution of vascular 
endothelial cells, digestion system, and human 
brain. Recombinant erythropoietin is effectual in 
treatment, prevention, and stabilization of 
hemoglobin and hematocrit levels in premature 
neonates and prevents a need for blood transfusion. 
The objective of the present study was to determine 
the effectiveness of injectable recombinant 
erythropoietin with oral iron in the perfusion of 
premature neonates.  
Materials and Methods 
This study was a randomized double-blinded 
clinical experiment, and the research context was 
NICU unit of Bou-Ali and Alavi hospitals in 
Ardabil city. Participants were 80 hospitalized 
neonates who weighed below 1500 g. They were 
randomly divided into two groups, each including 
40 individuals. The first group, i.e., experimental 
group, received injectable recombinant 
erythropoietin with a dosage of 400 IU per kilogram 
of weight in a day (three days a week) and oral iron, 
and the second group, i.e. control group, merely 
received oral iron. At study outset hemoglobin and 
serum iron levels as well as reticulocyte and serum 
ferritin percentages were measured for both groups, 
during discharge, and three months after discharge. 
The data were, then, analyzed in SPSS software, 
version 16 through performing statistical tests 
including t-tests, chi-squares, repeated-measures 
tests, and descriptive statistics. Results were 
presented in tables and figures. Significance level 
was set at less than 0.05. 
Results 
25 neonates (62.5%) in experimental group and 
24 (60%) in control group were boy. Most of 
mothers were in 20-25 age groups. Results showed 
that all of variables is matched in two groups (Table 
1). 
 
Table 1: Demographic data of neonates in two study groups  
Variables Experimental Control p-value 
Sex             Boy 
                   Girl  
25(62.5) 
15(37.5) 
24(60) 
16(40) 
0.8 
Mother Age Groups 
<20 
20-25 
25-30 
>30 
25.8  8.3 
 
8(20) 
18(45) 
5(12.5) 
9(22.5) 
24.5 5.6 
 
7(17.5) 
23(57.5) 
2(5) 
8(20) 
0.56 
Neonates Weight 1273.8 198.4 1223.8 217.5 0.68 
Apgar Score 
<4 
4-8 
>8 
 
2(5) 
23(57.5) 
15(37.5) 
 
4(10) 
19(47.5) 
17(42.5) 
0.26 
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The mean of hemoglobin level was 16.5 1.28 
mg/dl for control group and 16.8 1.6 mg/dl for 
experimental group. These levels decreased for both 
groups three months after discharge, and the rate of 
decreasing was statistically significant for both 
groups (figure 1). The mean of serum iron was 
94.7 18.8 μg/dl for control group and 88.2 12.1 
μg/dl for experimental and the rate of decreasing 
was statistically significant for the control group, 
but non-significant for experimental group after 
three mount late (figure 2). The mean of ferritin 
level was 104.5 23 in control group and 
133.7 34.4 in experimental group at study outset. 
In control group 25 neonates (62.5%) had ferritin of 
25-100 ng/ml, and in experimental group 29 
neonates (72.5%) had 101-200 ng/ml ferritins. 
These numbers decreased three months after 
discharge and the decrease was statistically non-
significant for the experimental group but 
significant for control group (figure 3). At study 
outset, the mean percentage of reticulocyte was 
7.5 4 for control group and 9.8 3.5 for 
experimental group. At study outset, most neonates, 
87.5% in experimental group and 60% in control 
group had a reticulocyte level higher than normal 
which decreased three months after discharge, and 
the rate of decreasing was statistically significant 
for both groups (figure 4). During discharge, 77.5% 
of participants in the experimental group had 
normal hemoglobin level, and 60% of those in the 
control group had a decreased level of hemoglobin. 
Hemoglobin level had decreased in both groups due 
to physiologic anemia which usually happens in 
neonates, but the decrease was greater for control 
group. The results of repeated-measured tests 
revealed that hemoglobin and ferritin levels as well 
as reticulocyte percentage had significantly changed 
during targeted phases but that serum iron level had 
minimally changed (Table 2). In the experimental 
group 13 neonates (32.5%) and in the control group 
23 cases (57.5%) needed transfusion and received 
blood. The difference between the two groups was 
statistically significant in this regard (P=0.024). 
 
 
Table 2: Change of blood results in groups in all study times 
P-Value Control Case Time study Variables 
0.001 16.5 16.8 Start of study Hb 
12.7 13.7 Discharge 
9.4 13.1 Three mount late 
0.14 94.7 88.2 Start of study Iron 
81.1 82.3 Discharge 
69.9 86.1 Three mount late 
0.001 104.5 133.7 Start of study Ferritin  
91.8 124.2 Discharge 
74.3 130 Three mount late 
0.001 7.5 9.8 Start of study Reticulocyte 
2.2 2.7 Discharge 
1.5 2.1 Three mount late 
 
 
 
Discussion 
The present study revealed that 400 units of 
injectable recombinant erythropoietin per kilogram 
of weight in a day (3 days a week) significantly 
increased reticulocyte number and prevented an 
increase of ferritin and hemoglobin levels in 
premature neonates with low birth weight. Three 
months after discharge, mean serum level of ferritin 
was higher in erythropoietin group (130) than 
control (75.3), and the need for transfusion 
significantly decreased in erythropoietin group. 
Likewise, Ballin et al., in a clinical experiment, 
found that reticulocyte count was higher in 
erythropoietin group (8.6%) than in control group 
